Clinical Trial Update: SP Resistance and Falciparum Malaria Transmission [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sulfadoxine-pyrimethamine resistance and falciparum malaria transmission has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• Sulfadoxine-pyrimethamine (sulfadoxine-pyrimethamine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Malaria | Phase 3 | Status: WITHDRAWN